TY - JOUR T1 - Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.200369 SP - jrheum.200369 AU - Rosie Scuccimarri AU - Evelyn Sutton AU - Mary-Ann Fitzcharles Y1 - 2020/04/02 UR - http://www.jrheum.org/content/early/2020/04/01/jrheum.200369.abstract N2 - Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3]. ER -